VLX1570, also known as VLX-1570, is a small molecule inhibitor that has been studied for its potential therapeutic properties in the treatment of various types of cancers. This article will provide an overview of VLX1570, including its chemical name, molecular formula, formula weight, CAS number, top ten keywords from Google and synonyms, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.
Chemical Name: The chemical name of VLX1570 is (2S)-2-((3-(4-((5-chloro-2-(phenylamino)pyrimidin-4-yl)amino)phenoxy)propyl)(methyl)amino)-3-phenylpropanoic acid.
Molecular Formula: The molecular formula of VLX1570 is C30H31ClN6O4.
Formula Weight: The formula weight of VLX1570 is 581.06 g/mol.
CAS No: The CAS number of VLX1570 is 1431280-51-1.
Top Ten Keywords from Google and Synonyms:
Synonyms for VLX1570 include (2S)-2-((3-(4-((5-chloro-2-(phenylamino)pyrimidin-4-yl)amino)phenoxy)propyl)(methyl)amino)-3-phenylpropanoic acid, VLX-1570, and 1431280-51-1.
Health Benefits of this Product: VLX1570 has shown potential as a cancer therapy agent. It functions as an inhibitor of the ubiquitin-proteasome system, which is responsible for the degradation of proteins within cells. By inhibiting this system, VLX1570 can interfere with the survival and growth of cancer cells. Additionally, preclinical studies have suggested that VLX1570 may be effective against drug-resistant cancer cells.
Potential Effects: The potential effects of VLX1570 on cancer cells include inhibition of cell division and induction of apoptosis, or programmed cell death. In preclinical studies, VLX1570 has demonstrated activity against multiple types of cancer, including multiple myeloma, acute myelogenous leukemia, and ovarian cancer. However, additional research is needed to determine the full range of potential effects of VLX1570 on cancer cells.
Product Mechanism: VLX1570 functions as an inhibitor of the ubiquitin-proteasome system, specifically targeting the proteasome. The proteasome is a large protein complex responsible for the degradation of intracellular proteins. By inhibiting the proteasome, VLX1570 interferes with the survival and growth of cancer cells, leading to inhibition of cell division and induction of apoptosis.
Safety: The safety profile of VLX1570 has not been extensively studied in humans. However, preclinical studies have suggested that the compound has low toxicity and is generally well-tolerated. Like all medications, VLX1570 may cause side effects in some individuals.
Side Effects: The potential side effects of VLX1570 are not well-defined, as the compound has not been extensively studied in humans. However, preclinical studies have suggested that the compound has low toxicity and is generally well-tolerated. Common side effects of proteasome inhibitors include fatigue, nausea, and diarrhea.
Dosing Information: The optimal dosing regimen of VLX1570 has not been established. Preclinical studies have suggested that the compound is most effective when administered in combination with other cancer therapies, such as chemotherapy or radiation therapy. The appropriate dose and duration of treatment with VLX1570 may vary depending on the type and stage of cancer being treated.
Conclusion: In conclusion, VLX1570 is a small molecular inhibitor that has shown promise as a cancer therapy agent in preclinical studies. The compound functions by inhibiting the ubiquitin-proteasome system and interfering with the survival and growth of cancer cells. Although the safety profile and optimal dosing regimen of VLX1570 have yet to be established, the compound may offer a new approach to the treatment of various types of cancers, particularly in cases where traditional therapies have been ineffective.
